Bavarian Nordic A/S is having a bit of a meme-stock moment, with retail traders buying up shares in the monkeypox vaccine maker as cases of the virus steadily rise.
Shares in the Danish biotech, which makes the only monkeypox vaccine approved by the US Food and Drug Administration (FDA), have gained 69% since hitting a low in early May. At the same time, cases of the virus have jumped from just a handful in Europe at the start of last month to more than 1,200 cases, mostly in men, across the region, as well as in the Americas, the Middle East, and Australia by early June.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Novo Nordisk denied general conditional reimbursement for Wegovy in Denmark – again
The Danish Medicines Agency has been told for the second time that the price of the obesity drug is not in line with the effect it provides.
Genmab to submit cancer candidate epcoritamab to the FDA before year-end
The US Food and Drug Administration will receive a marketing authorization application from Genmab and its partner Abbvie in the second half of this year.
Bavarian Nordic is working with EMA on monkeypox vaccine label expansion
Bavarian Nordic’s smallpox vaccine Imvanex has previously been used off-label to protect close contacts from monkeypox in several countries. The Danish vaccine firm is now working with the EMA to expand the label in an ”accelerated process.”
Leo Pharma eczema treatment recommended in two UK countries
After postponing the decision in April, the British medicines council NICE has now ruled that Adtralza can be recommended to treat atopic dermatitis.
Fujifilm invests USD 1.5bn in Danish factory
Japanese firm Fujifilm Diosynth Biotechnologies is investing DKK 11bn (USD 1.5bn) in its factor in Northern Zealand, Denmark. The expansion will provide 450 jobs.
Principal Scientist – Pharmacology 
Medical Advisor 
QA Senior Specialist 
Corporate Quality Compliance Specialist for Audit Management 
(Sr) Clinical Trial Manager 
Senior Scientist for Analytical Development 
Nordic Medical Advisor 
Senior Manager/Associate Director, Global Regulatory Affairs, CMC 
Global Product Manager - Pulmonology 
Project Managers keep all of us healthy 
Regulatory Affairs Manager - Maternity Cover